Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

Fig. 3

Clinical course of subject No.3. CT images of target lesion in lung at (a) enrollment in the study, (b) 11.1 months after enrollment (58 % decrease in sum of diameters), (c) 22.5 months after enrollment (46 % increase in sum of diameters). MCS: Mesenchymal chondrosarcoma, VDC: vincristine, doxorubicin and cyclophosphamide, IE: ifosfamide and etoposide. : Administration of trabectedin. ---: Borderline of 30 % decrease in sum of diameters

Back to article page